Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
Mouhamad NasserSophie LarrieuLoic BousselSalim Si-MohamedFabienne BazinSébastien MarqueJacques MassolFrançoise Thivolet-BejuiLara ChalabreysseDelphine Maucort-BoulchEric HachullaStéphane JouneauKatell Le LayVincent CottinPublished in: Respiratory research (2021)
This large, real-world, longitudinal study provides important insights into the characteristics, epidemiology and healthcare resource utilisation and costs associated with PF-ILD in France using a comprehensive and exhaustive database, and provides vital evidence that PF-ILD represents a high burden on both patients and healthcare services. Trial registration ClinicalTrials.gov, NCT03858842. ISRCTN, ISRCTN12345678. Registered 3 January 2019-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03858842.
Keyphrases
- interstitial lung disease
- healthcare
- systemic sclerosis
- rheumatoid arthritis
- risk factors
- idiopathic pulmonary fibrosis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- primary care
- prognostic factors
- computed tomography
- study protocol
- cardiovascular disease
- magnetic resonance imaging
- randomized controlled trial
- magnetic resonance
- image quality
- social media
- electronic health record
- adverse drug